Literature DB >> 7180942

Alterations in activities of anaphylatoxin inactivator and chemotactic factor inactivator during hemodialysis.

J R McCormick, D L Kreutzer, H J Keating, J Hupp, A Despins, M Moore.   

Abstract

The systemic infusion of complement-derived anaphylatoxin ane chemotaxins during hemodialysis results in profound transient neutropenia and may be associated with subtle pulmonary dysfunction. The fact that these potent inflammatory peptides do not usually produce serious ill effects may be due in part to their rapid inactivation by the serum regulatory proteins anaphylatoxin inactivator (AI) and chemotactic factor inactivator (CFI). Accordingly, the authors investigated the effect of hemodialysis on circulating neutrophil counts and serum levels of AI and CFI activity in 10 patients. In all patients, circulating neutrophil counts plummeted by more than 50% within 5 minutes of the onset of dialysis and rose beyond control levels by 1 hour. AI activity significantly fell from 65 +/- 16 mU/ml before dialysis to 18.7 +/- 7.8 mU/ml within 5 minutes of its initiation; levels remained depressed throughout the procedure. In contrast, CFI gradually increased, achieving a level significantly different from the predialysis value by 15 minutes. These events contrasted with the observation that activation of the complement system in vitro results in a significant decline in both CFI and AI activities. We suggest that the maintenance of or increase in CFI activity in patients undergoing hemodialysis enhances the clearance of circulating chemotactins, preventing the persistent activation of neutrophils during the procedure and subsequent organ dysfunction.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7180942      PMCID: PMC1916121     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  22 in total

1.  Arterial oxygenation during hemodialysis.

Authors:  N M Aurigemma; N T Feldman; M Gottlieb; R H Ingram; J M Lazarus; E G Lowrie
Journal:  N Engl J Med       Date:  1977-10-20       Impact factor: 91.245

2.  Serum carboxypeptidase B: a spectrophotometric assay using protamine as substrate.

Authors:  N C Corbin; T E Hugli; H J Müller-Eberhard
Journal:  Anal Biochem       Date:  1976-05-21       Impact factor: 3.365

3.  Chemotactic factor inactivators of human granulocytes.

Authors:  J P Brozna; R M Senior; D L Kreutzer; P A Ward
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

Review 4.  Immunopathogenesis of hypersensitivity pneumonitis.

Authors:  R C Roberts; V L Moore
Journal:  Am Rev Respir Dis       Date:  1977-12

5.  Isolation by hydrophobic chromatography of the chemotactic factor inactivators from human serum.

Authors:  D L Kreutzer; W D Claypool; M L Jones; P A Ward
Journal:  Clin Immunol Immunopathol       Date:  1979-02

6.  Carboxypeptidase B-like activity and C3 in cystic fibrosis.

Authors:  J Lieberman
Journal:  Am Rev Respir Dis       Date:  1975-01

7.  Suppression of immune complex-induced inflammation by the chemotactic factor inactivator.

Authors:  K J Johnson; T P Anderson; P A Ward
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

8.  Regulatory dysfunction in leukotaxis.

Authors:  P A Ward; K J Johnson; D L Kreutzer
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

9.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.

Authors:  V A Bokisch; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

10.  Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis.

Authors:  P R Craddock; J Fehr; K L Brigham; R S Kronenberg; H S Jacob
Journal:  N Engl J Med       Date:  1977-04-07       Impact factor: 91.245

View more
  1 in total

1.  Decreased synthesis of serum carboxypeptidase N (SCPN) in familial SCPN deficiency.

Authors:  K P Mathews; J G Curd; T E Hugli
Journal:  J Clin Immunol       Date:  1986-01       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.